Skip to main content
Canna~Fangled Abstracts

Clinical uses of cannabis and cannabinoids in the United States.

By January 30, 2020February 12th, 2020No Comments
2020 Jan 30;411:116717. doi: 10.1016/j.jns.2020.116717.
[Epub ahead of print]

Abstract

The role of cannabis in medicine is rapidly evolving. Medical cannabis is now legal in a majority of states, and THC and CBD, the prominent cannabinoids found in cannabis, have both been utilized in the development of FDA-approved drugs. Due to the complicated legal status of cannabis and cannabinoids, as well as regulations that vary from state to state, the appropriate use of these substances for both patients as well as clinicians is often unclear. Advancements in the understanding of the pharmacology of cannabis have led to numerous proposed uses of these drugs, including as antidepressant or analgesic agents. However, clinical trial data for these substances suggests that many purported indications of cannabis and cannabinoids are not supported by good clinical data. Furthermore, cannabis and several cannabinoid-based medications have potentially concerning side effect profiles that may limit their use in certain patient populations. As the legal status and clinical database of these medications continue to evolve, physicians will need to continue to balance the real potential of these compounds with their limitations and adverse effects.

KEYWORDS: CBD, Cannabidiol, Cannabinoids, Cannabis, Delta-9-tetrahydrocannabinol, THC

PMID: 32044684
DOI: 10.1016/j.jns.2020.116717

Publication type

Publication type

Leave a Reply